A carregar...
B cell non-Hodgkin's lymphoma: rituximab safety experience
A substantial body of data supports use of rituximab as first-line and maintenance therapy for the treatment of indolent non-Hodgkin's lymphoma. With 7 years of postmarketing surveillance experience and more than 370,000 patient exposures, the safety profile of rituximab is well defined. Severa...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2005
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2833973/ https://ncbi.nlm.nih.gov/pubmed/15960818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar1739 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|